Sanofi SA (NYSE: SNY) is in the midst of a transition that it hopes will return it to business income growth in 2019. The French biopharma is one of the biggest drugmakers in the world, but its shares have suffered lately because of patent expiration. Is now a good time to pick this stock up on sale?In this clip from The Motley Fool's Industry Focus: Healthcare, Kristine Harjes and Todd Campbell dig into Sanofi's past, present, and future for clues.A full transcript follows the video.Continue reading
Similar Stories to Is This European Drug Stock Giant A Buy? on Bing News
newsfeedback@fool.com (Motley Fool Staff), The Motley Fool
Mon, 05/21/2018 - 4:18am
BING NEWS:
- Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Stock market giants including Nvidia and Walmart completed stock splits in 2024. Investors like these operations because they lower the per-share price, making a stock more accessible for a broader ...
12/29/2024 - 8:30 pm | View Link - Stock Market Today: Dow Jones Surges As Broadcom Lifts; Drug Giant Climbs A Second Day After FDA Nod (Live Coverage)
The Dow Jones Industrial Average and other major indexes remained mixed Monday afternoon on a holiday-shortened week. An Nvidia chip supplier broke out of a base on the stock market today while shares ...
12/23/2024 - 8:20 am | View Link - Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging
Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more.
12/20/2024 - 6:25 am | View Link - Novo Nordisk stock plunges 20% after a trial of its latest weight loss drug disappoints
The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, below expectations for 25%.
12/20/2024 - 2:00 am | View Link - Novo Nordisk stock price takes a tumble after the Wegovy maker’s next-generation weight-loss drug underwhelms
CagriSema, a drug that Novo had hoped would become the next generation weight-loss aid, failed to meet expectations in late-stage trials ...
12/20/2024 - 1:24 am | View Link - More
Welcome to Wopular
Wopular is an
online newspaper rack,
giving you a summary view of the top headlines from the top news sites.
Senh Duong (Founder)
Wopular,
MWB,
RottenTomatoes
MoviesWithButter : Our Sister Site
- "Expendables 4" Starts Shooting This Fall, Says Randy Couture at the Arnold Sports Festival more
- “Expendables 4” Gets Funding Interest from “Ip Man 3” Financier more
- "Ip Man 3" Distributor Suspected of Box Office Fraud, Parent Company Loses $200M in Market Cap more
- Yen Targets "Ip Man 4" for 2018 Release; Discusses Film with Director, Producer more
- "Ip Man 3" Shatters Expectations with $72M Opening [China Box Office] more